Also known as: IBI362 · OXM3
Mazdutide (IBI362/OXM3) is a GLP-1/glucagon dual receptor agonist developed by Innovent Biologics (China), based on an oxyntomodulin-inspired sequence. It achieved 11.3% weight loss in Chinese adults over 24 weeks (Phase 2). Approved in China for T2D (2024) and in Phase 3 trials for obesity and MASLD.
Mazdutide is based on the naturally occurring gut hormone oxyntomodulin — a peptide derived from proglucagon cleavage that activates both GLP-1 and glucagon receptors. Mazdutide received conditional approval from China's NMPA in 2024 for the treatment of type 2 diabetes — one of the first GLP-1/glucagon dual agonists to reach market approval globally.
Activates GLP-1R in the pancreas (glucose-dependent insulin secretion), gut (slowed gastric emptying), and CNS (hypothalamic appetite suppression).
Simultaneous GCGR activation drives hepatic fatty acid beta-oxidation, increases thermogenesis, and promotes lipolysis. The GLP-1 component prevents hyperglycemia that would occur with glucagon agonism alone.
Phase 2b MASLD trials showed significant reductions in MRI-PDFF liver fat fraction, outperforming pure GLP-1 agents for liver disease endpoints.
Mazdutide is currently approved only in China. Development outside China has not been licensed as of 2024. Its GLP-1/glucagon dual agonism provides weight loss and metabolic benefit with particular strength on liver fat reduction and MASLD endpoints — where pure GLP-1 agents show less efficacy. GI adverse effects (nausea, vomiting) are the primary dose-limiting factor during escalation.
Consistent with the GLP-1 class, mazdutide is intended for chronic maintenance therapy. The approved T2D indication in China follows the same chronic-use model as Ozempic and Mounjaro. No cycling protocols have been established for the obesity indication; weight regain upon discontinuation is expected based on class data.
Phase 2b GLORY-1 (332 Chinese adults, 24 weeks): 11.3% weight loss at 9 mg vs. 1.8% placebo. NMPA conditional approval for T2D in 2024. MASLD Phase 2b MERMAID showed superiority on liver fat and fibrosis endpoints.
Ask anything about Mazdutide — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…